Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05374681
Other study ID # 29BRC22.0028
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 28, 2023
Est. completion date September 28, 2026

Study information

Verified date February 2024
Source University Hospital, Brest
Contact jean-Christophe GENTRIC, PhD
Phone 0298347520
Email jean-christophe.gentric@chu-brest.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic subdural hematomas (CSH) are collections of blood in the subdural space. CSH are becoming the most common cranial neurosurgical condition among adults, and a significant public health problem, due to an increasing use of anticoagulant and antiplatelet medication in an ageing population. Symptomatic CSH, or CSH with a significant mass effect, are treated surgically. However, recurrences are common (10 to 20%). Conservative management (medical) is used in patients who are asymptomatic or have minor symptoms. However, therapeutic failures, requiring surgical treatment, are common. The pathophysiology of CSH involves inflammation, angiogenesis, and clotting dysfunction. Self-perpetuation and rebleeding is thought to be caused by neo-membranes from the inflammatory remodeling of the dura-mater mainly fed by the distal branches of the middle meningeal artery (MMA). There are 13 ongoing registered RCTs in CSH, with the most common covering application of steroids, surgical techniques and tranexamic acid. Further to this, there are trials running on other pharmacological agents, and peri-operative management. Some industrial or academic trials are or will enroll in France in the next year in France. But to our best knowledge, none of these trials will the eventual benefits of the MMA embolization in both cases of medical and/or surgical management, and none will focus on the use of cyanoacrylates (CYA) for this purpose. Preliminary case series and nonrandomized retrospective studies have suggested that MMA embolization alone or as adjuvant therapy to surgery can decrease recurrences. The investigators hypothesize that in both conditions of conservative or surgical managements, endovascular embolization of patients with CSH significantly reduces the risk of recurrence of CSH. The investigators choose the CYA as liquid embolic agent because of the pain and cost of the use of Ethylen Vinyl alcohol copolymer (EVOH) agents and its simplicity to be used.


Description:

- Indication of surgical or conservative management will be decided by the neurosurgeon. - Experimental arm: CSH requiring hematoma removal will be surgically managed with a surgical technique applied depending on the surgeon's discretion. Medical management will be adopted according to neurosurgeons habits. MMA embolization (on the CSH side or bilaterally if necessary) in the Experimental Arms will be performed with Cyanoacrylates and preferentially using conscious sedation or local anesthesia. • Control arm: CSH requiring hematoma removal will be surgically managed with a surgical technique applied depending on the surgeon's discretion. Medical management will be adopted according to neurosurgeons habits • Primary and secondary end points will be assessed at 2 months+/- 1 month and assessed at 6 +/- 2 months. The blind items will be the mRS and the RACE score. The volume of the CSH will be semi-automatically assessed using the ABC/2 method and the estimated maximal thickness of the CSH on axial images.


Recruitment information / eligibility

Status Recruiting
Enrollment 550
Est. completion date September 28, 2026
Est. primary completion date September 28, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient with a more than 10 mm CSH confirmed by NCCT - CSH localized to convexity - Patient aged 18 years or more at the time of the enrollment - Patient beneficiary from health insurance Exclusion Criteria: - Any contraindication as required per angiogram procedure (severe renal failure, allergy…) - Pre-existing severe disability resulting in baseline mRS score > 3 - Life expectancy of less than 6 months due to another cause than CSH - Patient under legal protection or deprived of liberty by a judicial or administrative decision - Pregnant or breastfeeding women

Study Design


Intervention

Other:
Medical treatment
Medical treatment alone
Surgical treatment
Surgical treatment alone
embolization of the MMA
The middle meningeal artery will be catheterized then embolized by cyanoacrylates until the occlusion of the MMA.

Locations

Country Name City State
France CHU Amiens-Picardie Amiens
France CHU Bordeaux Bordeaux
France CHU Brest Brest
France CHU Caen Caen
France CHU Nancy Nancy
France CHU Nantes Nantes
France Hôpital Pitié Salpêtrière Paris
France CHU Tours Tours
Martinique CHU Martinique Fort-de-France

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Brest

Countries where clinical trial is conducted

France,  Martinique, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of CSH recurrence defined by the composite endpoint CSH recurrence defined by the composite endpoint:
A symptomatic CSH during the 6 month FU period
A secondary surgical management during the 6 months FU period
A remaining or reaccumulated hematoma on NCCT at 6 months
At 6 month
Secondary Number of symptomatic CSH during the FU period Number of symptomatic CSH during the FU period At 6 month
Secondary Number of secondary surgical management during the FU period Number of secondary surgical management during the FU period At 6 month
Secondary Number of remaining or reaccumulated hematoma on NCCT Number of remaining or reaccumulated hematoma on NCCT At 6 month
Secondary Clinical efficacy Mortality rate At 6 month
Secondary Clinical efficacy Shift Modified Rankin Scale (mRS) (min = 0 = better outcome, max = 5 = worse outcome) At 6 month
Secondary Clinical efficacy Rapid Arterial oCclusion Exam (RACE) score evaluation (min = 0 = better outcome, max = 9 = worse outcome) At 6 month
Secondary Clinical efficacy Quality of life of patients will be evaluated by the EuroQol-5Dimensions-5L questionnaire At 6 month
Secondary Clinical efficacy Neurological exam : Barthel Scale (min = 0 = worse outcome, max = 100 = better outcome) At 6 month
Secondary Success rate of the embolization (success = technical success of the procedure. Failure of the procedure = total or partial (catheterization, injection, other)). Success rate of the embolization (success = technical success of the procedure. Failure of the procedure = total or partial (catheterization, injection, other)). At 6 month
Secondary Complication rate of the embolization Complication rate of the embolization At 6 month
Secondary Volumetry of the CSH, calculated by the ABC/2 method. Volumetry of the CSH, calculated by the ABC/2 method. At 6 month
Secondary Maximum thickness of the CSH in mm. Maximum thickness of the CSH in mm. At 6 month
Secondary Comparison of the rate of AE in both groups Comparison of the rate of AE in both groups At 6 month
Secondary Comparison of the rate of SAE in both groups Comparison of the rate of SAE in both groups At 6 month
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06347796 - Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study N/A
Recruiting NCT04065113 - Middle Meningeal Artery Embolization for Chronic Subdural Hematoma N/A
Recruiting NCT02938468 - Mgt of Chronic Subdural Hematoma Using Dexamethasone Phase 2/Phase 3
Completed NCT03307395 - Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma N/A
Terminated NCT04502745 - A Study to Evaluate Endoscope-assisted, Minimally-invasive Cortical Access System for Chronic Subdural Evacuation N/A
Terminated NCT03353259 - Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery Phase 2/Phase 3
Recruiting NCT02568124 - Tranexamic Acid in Chronic Subdural Hematomas Phase 2/Phase 3
Completed NCT02282228 - Detecting Chronic Subdural Hematoma With Microwave Technology N/A
Recruiting NCT05143216 - High Concentration Oxygen Therapy for Pneumocephalus in Chronic Subdural Haematoma: A Prospective Observational Study
Active, not recruiting NCT04816591 - Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA N/A
Recruiting NCT06401772 - The Effectiveness and Safety of Body Posture in Preventing Postoperative Recurrence for Chronic Subdural Hematoma N/A
Completed NCT06134206 - Burr Hole Ultrasound Study N/A
Recruiting NCT03666949 - General Anesthesia Versus Locoregional Anesthesia for Evacuation of Chronic Subdural Hematoma N/A
Recruiting NCT03280212 - Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma Phase 3
Completed NCT03447327 - Outcome of Single Burr Hole Under Local Anaesthesia in the Management of Chronic Subdural Hematoma N/A
Recruiting NCT05267184 - Swedish Trial on Embolization of Middle Meningeal Artery Versus Surgical Evacuation in Chronic Subdural Hematoma N/A
Not yet recruiting NCT05900557 - Neurologic Deficits and Recovery in Chronic Subdural Hematoma N/A
Completed NCT02757235 - The Swedish Study of Irrigation Fluid Temperature in the Evacuation of Chronic Subdural Hematoma N/A
Terminated NCT02111785 - Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma Phase 2/Phase 3
Recruiting NCT05599217 - Association Between Dietary Factors and Chronic Subdural Hematoma (DISH)